

Drug Information Sheet("Kusuri-no-Shiori")

Injection

Revised: 04/2022

The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment.

Brand name:LEUCOVORIN INJECTION 3mg

Active ingredient:Calcium folinate hydrate

Dosage form:injection

Print on wrapping:



Effects of this medicine

This medicine has no anticancer effect; however, it reduces the toxicity of methotrexate, antifolate, by reactivating nucleic acid synthesis in the cells.

It is usually used for reduction of the toxicity of antifolate.

The following patients may need to be careful when using this medicine.Be sure to tell your doctor and pharmacist.

- If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines or foods.
- If you are pregnant or breastfeeding.
- If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.)

Dosing schedule (How to take this medicine)

- Your dosing schedule prescribed by your doctor is((to be written by a healthcare professional))
- For conventional methotrexate therapy, CMF therapy, methotrexate therapy for rheumatoid arthritis and M-VAC therapy: In general, this medicine is injected intramuscularly 4 times at an interval of 6 hours, in the presence of any adverse reactions possibly due to methotrexate.
For methotrexate and leucovorin rescue therapy: In general, this medicine is injected intravenously 9 times at intervals of 3 hours, starting from 3 hours after the completion of methotrexate administration, and then this medicine is injected intravenously or intramuscularly 8 times at intervals of 6 hours.
For sequential methotrexate and 5-fluorouracil therapy: In general, this medicine is injected intravenously or intramuscularly 2 to 6 times at an interval of 6 hours, starting from 24 hours after the administration of methotrexate (24, 30, 36, 42, 48 and 54 hours after the administration of methotrexate).
- The treatment period with this medicine depends on your response to the treatment.

Precautions while taking this medicine

Possible adverse reactions to this medicine

The most commonly reported adverse reactions include rash, fever, redness, vascular pain (during intravenous injection) and transient pain (during intramuscular injection). If any of these symptoms occur, consult with your doctor or pharmacist.

The symptoms described below are rarely seen as initial symptoms of the adverse reactions indicated in brackets. If any of these symptoms occur, stop taking this medicine and see your doctor immediately.

- rash, breathing difficulty, decreased blood pressure (lightheadedness) [shock, anaphylaxis]

The above symptoms do not describe all the adverse reactions to this medicine. Consult with your doctor or pharmacist if you notice any symptoms of concern other than those listed above.

Storage conditions and other information

For healthcare professional use only / /

For further information, talk to your doctor or pharmacist.